List of Excipients in Branded Drug CAVERJECT IMPULSE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	CAVERJECT IMPULSE	alprostadil	0009-5181	ALFADEX
Pharmacia & Upjohn Company LLC	CAVERJECT IMPULSE	alprostadil	0009-5181	BENZYL ALCOHOL
Pharmacia & Upjohn Company LLC	CAVERJECT IMPULSE	alprostadil	0009-5181	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	CAVERJECT IMPULSE	alprostadil	0009-5181	LACTOSE

CAVERJECT IMPULSE Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: August 13, 2026

CAVERJECT IMPULSE is an alprostadil intracavernosal injection supplied in a dual-chamber, single-use syringe. Its commercial differentiation depends less on novel excipients than on reconstitution convenience, dose accuracy, sterility, device usability, and reliable low-dose delivery. The core formulation uses a small excipient system, leaving opportunities in preservative-free delivery, ready-to-use presentations, device engineering, packaging, and alternative dosage forms.

What is CAVERJECT IMPULSE and how is it formulated?

CAVERJECT IMPULSE contains alprostadil, also known as prostaglandin E1, at 10 mcg or 20 mcg per dose. The product is supplied as a sterile lyophilized powder and diluent in a dual-chamber syringe. The user mixes the components immediately before intracavernosal injection. The reconstituted volume is approximately 1 mL. [1]

Attribute	CAVERJECT IMPULSE
Active ingredient	Alprostadil
Therapeutic class	Intracavernosal erectile dysfunction therapy
Strengths	10 mcg and 20 mcg
Dosage form	Sterile powder plus diluent in dual-chamber syringe
Route	Intracavernosal injection
Administration	Single-use
FDA pathway	NDA drug-device combination product
Primary commercial differentiator	Integrated reconstitution and injection system
Preservative strategy	Single-use presentation minimizes the need for multidose preservation
Storage	Controlled room-temperature storage under the approved labeling
Target indication	Erectile dysfunction

The formulation is designed around the low dose and local route of administration. A typical systemic injectable formulation would require a substantially different concentration and stability strategy. CAVERJECT IMPULSE instead uses a dry powder presentation to improve stability before use.

The prescribing information identifies excipient components including lactose and citrate, with pH adjustment using hydrochloric acid and sodium hydroxide. The diluent is sterile water for injection. [1] Exact quantitative composition should be evaluated against the current approved product specification before development or regulatory submission.

What excipients are used in CAVERJECT IMPULSE?

The excipient system has four functional roles: bulking and cake formation, buffering, pH adjustment, and reconstitution.

Excipient or component	Likely formulation role	Commercial significance
Lactose	Bulking agent and lyophilized-cake support	Supports low-dose powder handling and visual presentation
Sodium citrate	Buffering and pH control	Helps maintain an injectable pH environment
Hydrochloric acid	pH adjustment	Used during formulation manufacture
Sodium hydroxide	pH adjustment	Used during formulation manufacture
Sterile water for injection	Reconstitution vehicle	Enables a dry-powder, single-use presentation

The key strategic point is the extremely low alprostadil dose. At 10 mcg or 20 mcg per syringe, excipient mass, powder uniformity, adsorption, content uniformity, and reconstitution performance can have a greater effect on product quality than the nominal active-ingredient quantity.

Why lactose is commercially relevant

Lactose is a conventional lyophilization excipient, but it is not automatically interchangeable with mannitol, sucrose, trehalose, or glycine. A replacement can change:

• cake structure;
• residual moisture;
• reconstitution time;
• alprostadil recovery;
• syringe visibility;
• particulate formation;
• stability during storage;
• compatibility with the dual-chamber device.

A generic or follow-on developer would need to establish that any excipient substitution does not affect dosage-form performance or clinical use. For an ANDA, the formulation does not need to copy every inactive ingredient, but differences must comply with FDA inactive-ingredient requirements and must not create safety, efficacy, or pharmaceutical-equivalence problems. [2]

Why the buffer system matters

Alprostadil is chemically sensitive to pH, oxidation, light, temperature, and aqueous exposure. The citrate system is therefore more than a passive excipient choice. A new buffer could create a product advantage, but it would require comparative data on:

• potency retention;
• degradation products;
• pH drift;
• reconstitution time;
• syringe and needle compatibility;
• extractables and leachables;
• local tolerability after intracavernosal injection.

Any formulation designed for extended aqueous shelf life would face a higher stability burden than the current dry-powder approach.

What formulation opportunities exist for CAVERJECT IMPULSE competitors?

The most credible opportunities are incremental. They involve improving patient handling and manufacturing economics without changing the pharmacology of alprostadil.

Ready-to-use aqueous alprostadil

A ready-to-use solution could eliminate the mixing step. Its commercial value would depend on achieving acceptable shelf life without excessive degradation or adsorption.

Potential advantages include:

• simpler patient administration;
• lower preparation error risk;
• faster use;
• easier integration with autoinjectors;
• improved suitability for specialty-pharmacy fulfillment.

The principal barriers are aqueous stability, preservative exposure, container compatibility, and maintaining low-dose content uniformity. A ready-to-use formulation would probably require a new formulation package rather than a simple excipient substitution.

Preservative-free multidose systems

A preservative-free multidose cartridge could reduce waste and improve convenience, but intracavernosal use creates a high sterility and contamination-control burden. The system would need validated microbial barrier performance, dose accuracy over repeated actuations, and protection against misuse.

This opportunity is commercially attractive but technically more difficult than a single-use syringe. A multidose system could also trigger new device and human-factors requirements.

Improved lyophilized formulations

A competitor could retain the dry-powder strategy while improving:

• shorter reconstitution time;
• lower residual moisture;
• reduced powder adhesion;
• better cake appearance;
• improved stability at temperature excursions;
• compatibility with a smaller syringe;
• reduced manufacturing cycle time.

Trehalose, sucrose, mannitol, glycine, or alternative citrate concentrations could be evaluated, but each change requires a complete formulation and stability assessment. The commercial advantage would be strongest if the change also reduces cost of goods or supports less restrictive distribution.

Lower-volume and higher-concentration presentations

A smaller injection volume could improve patient acceptance. The main issue is local tolerability. Increasing concentration may raise the risk of pain, tissue irritation, precipitation, or dose-delivery variability. A smaller-volume product could also require a new dose-conversion strategy and new instructions for use.

Combination products and delivery devices

Device-led differentiation is likely to be more defensible than a basic excipient change. Opportunities include:

• concealed-needle injectors;
• dose-limiting delivery systems;
• prefilled cartridges;
• pen-like delivery systems;
• low-force actuation;
• integrated needle protection;
• tactile and audible dose confirmation;
• packaging designed for discreet storage and transport.

Because CAVERJECT IMPULSE is already a drug-device combination product, a competing device would need to demonstrate reliable dose delivery and usability in the intended patient population. [1,3]

What patents protect CAVERJECT IMPULSE?

CAVERJECT IMPULSE is based on an older active ingredient and an established indication. The principal patent risk is therefore more likely to involve formulation, syringe architecture, reconstitution systems, manufacturing methods, or method-of-use claims than new-molecule exclusivity.

Public FDA records identify CAVERJECT IMPULSE as an approved alprostadil product, but FDA labeling does not establish a complete global patent estate. Patent protection must be assessed separately in the United States, Europe, Japan, Canada, and other commercial markets. [1,4]

Potential protection category	Relevance to CAVERJECT IMPULSE	Competitive risk
Alprostadil compound patents	Low for a legacy active ingredient	Generally limited by age and expiration
Erectile-dysfunction method patents	Potentially relevant	Usually vulnerable to expiration and carve-out strategies
Dry-powder formulation patents	Potentially relevant	Depends on claim scope and prosecution history
Dual-chamber syringe patents	Commercially important	May affect device substitution
Reconstitution method patents	Potentially relevant	Can be designed around if claims are narrow
Packaging and needle-protection patents	Moderate	Often avoidable through alternative designs
Manufacturing process patents	Product-specific	Can create supply-chain barriers even after composition patents expire
Trademark protection	Ongoing commercial protection	Does not prevent lawful generic competition

A reliable patent analysis requires checking the current FDA Orange Book, USPTO Patent Center, issued patents, terminal disclaimers, patent-term adjustments, litigation records, and foreign registers. Patent expiration should not be inferred from the age of the active ingredient alone.

Are there Orange Book-listed patents for CAVERJECT IMPULSE?

The Orange Book is the relevant U.S. source for patents and regulatory exclusivities associated with approved small-molecule drug products. [4] A current Orange Book review should distinguish:

1. patents listed against the relevant NDA;
2. patents listed against the specific dosage form or strength;
3. expired patents;
4. unexpired formulation or device-related patents;
5. use patents that may be addressed through a section viii statement;
6. patents that can support a Paragraph IV certification.

For an alprostadil product with an old active ingredient, any remaining Orange Book risk is more likely to arise from product presentation or use claims than from the molecule itself.

When does CAVERJECT IMPULSE lose exclusivity?

The active ingredient is an established prostaglandin and does not provide new-molecular-entity exclusivity for a modern CAVERJECT IMPULSE competitor. FDA exclusivity and patent rights must be separated.

Exclusivity type	Relevance
New chemical entity exclusivity	Not applicable to established alprostadil
Five-year NCE exclusivity	Not applicable
Three-year clinical-investigation exclusivity	Depends on the specific approval and supporting studies
Orphan-drug exclusivity	Not applicable to the erectile-dysfunction indication
Pediatric exclusivity	Depends on any FDA grant associated with the NDA
Patent exclusivity	Depends on live, listed, and enforceable claims
Trademark exclusivity	Continues independently of generic approval

A generic launch date cannot be determined from the brand name or original approval date. It depends on the live patent set, the ANDA filing date, the type of certification, FDA review, tentative or final approval, and any litigation stay.

What Paragraph IV challenges and generic entry risks exist?

A generic applicant could pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the product. The main regulatory questions are likely to involve the combination of:

• alprostadil strength;
• powder and diluent configuration;
• syringe functionality;
• reconstitution procedure;
• injection volume;
• needle or delivery system;
• inactive ingredients;
• labeling and instructions for use.

A Paragraph IV certification would be relevant only to unexpired patents listed in the Orange Book. If a listed patent covers an approved method of use, a generic applicant may consider a section viii statement and omit the protected indication where legally and regulatorily permitted. The commercial value of that strategy depends on whether the remaining label still supports a viable market.

The most plausible launch scenarios are:

Scenario	Timing profile	Commercial effect
Formulation-and-device generic	Requires broader development and device validation	Potentially slower but differentiated
Same basic dry-powder presentation	Lower formulation risk	Greater price competition
Ready-to-use solution	New stability and packaging burden	Could compete on convenience
Compounded alprostadil	May reach some patients outside the approved product channel	Quality, sterility, and consistency vary by source
Alternative intracavernosal product	Competes without direct generic substitution	Can target convenience or price

How strong is the CAVERJECT IMPULSE patent estate?

The estate appears structurally weaker around the alprostadil molecule and stronger around product execution. The commercial defensibility of CAVERJECT IMPULSE is likely to depend on the combined effect of:

• device integration;
• approved labeling;
• manufacturing know-how;
• supplier qualification;
• sterility controls;
• patient familiarity;
• reimbursement and distribution;
• brand recognition.

Formulation claims are strongest when they require a specific excipient ratio, pH range, residual-moisture profile, degradation threshold, or reconstitution performance that competitors cannot easily reproduce. Broad claims to alprostadil in an injectable formulation are more vulnerable to prior art and design-around strategies.

Device claims can be valuable if they cover the dual-chamber architecture, mixing sequence, dose delivery, or safety mechanism. A competitor may still avoid infringement through a vial-and-syringe kit, cartridge, or separate prefilled components.

What FDA regulatory status does CAVERJECT IMPULSE have?

CAVERJECT IMPULSE is an FDA-approved prescription product for erectile dysfunction. The approval covers alprostadil delivered by intracavernosal injection through the labeled presentation. [1]

FDA regulatory issues for a follow-on product include:

• whether the product is pharmaceutically equivalent;
• whether the device is sufficiently comparable;
• whether a new drug-device combination requires a 505(b)(2) application;
• whether a generic device can be approved through the ANDA pathway;
• whether the proposed formulation creates new inactive-ingredient concerns;
• whether human-factors data are needed;
• whether the proposed labeling preserves the approved use.

The regulatory pathway becomes less predictable when a developer changes the delivery system, concentration, reconstitution method, or dosing instructions. A product that cannot demonstrate equivalence to the reference presentation may require a 505(b)(2) strategy rather than a conventional ANDA.

What commercial opportunities exist in the CAVERJECT IMPULSE market?

The strongest opportunities are likely to come from convenience and access rather than pharmacologic differentiation.

Specialty-pharmacy and telehealth distribution

Alprostadil injection requires patient training and repeat supply. A manufacturer could compete through discreet fulfillment, automated refills, injection education, and integrated disposal packaging. These services do not create formulation exclusivity but can reduce patient abandonment.

Combination packaging

A kit containing the syringe, needle, alcohol swab, disposal container, and concise instructions could address use errors. The kit may be particularly useful for first-time patients and specialty-pharmacy channels.

Device licensing

A device company with a compact mixing or injection platform could license the technology to a generic or 505(b)(2) developer. The commercial value would increase if the platform can support other low-dose injectable products.

Manufacturing partnerships

The most important manufacturing assets are likely to include:

• sterile fill-finish capability;
• dual-chamber syringe assembly;
• lyophilization capacity;
• low-dose content-uniformity controls;
• container-closure testing;
• validated particulate and sterility controls.

These capabilities can create entry barriers even when composition patents have expired.

Geographic expansion

The product opportunity differs by market. U.S. entry depends heavily on Orange Book patents and ANDA eligibility. European entry depends on national or centralized regulatory strategy, local reference-product status, device requirements, and national reimbursement. In emerging markets, supply reliability, cold-chain avoidance, price, and physician training may be more important than patent exclusion.

How does CAVERJECT IMPULSE compare with competing erectile-dysfunction drugs?

Product category	Active ingredient	Administration	Main advantage	Main limitation
CAVERJECT IMPULSE	Alprostadil	Intracavernosal injection	Direct local effect and established use	Injection burden and penile pain risk
Oral PDE5 inhibitors	Sildenafil, tadalafil, vardenafil, avanafil	Oral	Convenience and broad familiarity	Contraindications, variable response, systemic effects
Intraurethral alprostadil	Alprostadil	Urethral delivery	Avoids intracavernosal injection	Lower efficacy and local discomfort for some users
Compounded injection mixtures	Often alprostadil with other agents	Intracavernosal injection	Dose and price flexibility	Variable sourcing, sterility, and regulatory status
Vacuum erection devices	Mechanical	External device	Drug-free option	Usability and patient acceptance limitations

CAVERJECT IMPULSE retains a niche where oral therapy is ineffective, contraindicated, or unsuitable. A competitor that improves administration may capture value without changing alprostadil’s mechanism.

Key Takeaways

• CAVERJECT IMPULSE uses a low-dose alprostadil lyophilized formulation with lactose, citrate, pH-adjustment components, and sterile water for reconstitution.
• The dual-chamber syringe is central to the product’s commercial differentiation.
• The strongest formulation opportunities are ready-to-use solutions, improved lyophilized cakes, lower-volume presentations, and preservative-free multidose systems.
• The main technical barriers are alprostadil stability, low-dose uniformity, sterility, reconstitution performance, and device compatibility.
• Patent risk is more likely to involve formulation, delivery-device, manufacturing, and method-of-use claims than the alprostadil molecule.
• Generic entry may proceed through an ANDA, but substantial device or formulation changes could support a 505(b)(2) strategy instead.
• Commercial opportunities are concentrated in device licensing, specialty-pharmacy distribution, patient training, packaging, and sterile manufacturing.

FAQs

Can CAVERJECT IMPULSE excipients be replaced in a generic product?

Yes. A generic product does not necessarily need identical inactive ingredients, but any substitution must satisfy FDA requirements for safety, pharmaceutical equivalence, product performance, and labeling.

Is a preservative required in an alprostadil injection?

Not necessarily. CAVERJECT IMPULSE uses a single-use presentation, which reduces the need for a multidose antimicrobial preservative. A multidose product would require a separate sterility and container-closure strategy.

Can alprostadil be supplied as a prefilled liquid syringe?

Potentially, but the developer must address aqueous stability, adsorption, degradation, container compatibility, particulate control, shelf life, and dose accuracy. The regulatory pathway may differ from a direct generic approach.

Does a new CAVERJECT IMPULSE device require clinical trials?

Not always. The requirement depends on the degree of device and formulation change, equivalence to the reference product, human-factors risk, and FDA pathway. A material change in dose delivery or instructions can increase the evidence burden.

Is compounded alprostadil a direct substitute for CAVERJECT IMPULSE?

Compounded products may contain alprostadil or combination formulations, but they are not automatically therapeutically, technically, or regulatorily equivalent to the FDA-approved product. Differences can involve concentration, sterility controls, excipients, storage, packaging, and dosing instructions.

References

1. U.S. Food and Drug Administration. (2019). CAVERJECT IMPULSE (alprostadil) prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2023). Abbreviated new drug application regulations, 21 C.F.R. Part 314. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314

3. U.S. Food and Drug Administration. (2016). Applying human factors and usability engineering to medical devices: Guidance for industry and Food and Drug Administration staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book